Literature DB >> 23839611

Imatinib in neurofibromatosis type 2.

Stephanie Lim1, Paul de Souza.   

Abstract

A 30-year-old man with a 10-year history of neurofibromatosis type 2 (NF-2) and minimal hearing in his left ear, presented with rapidly progressive disease and risk of total hearing loss. He was started on imatinib and achieved stable disease for 4 months, after which the drug was ceased due to toxicity. He was then treated with bevacizumab for 8 months with a best response of stable disease.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23839611      PMCID： PMC3736214          DOI： 10.1136/bcr-2013-010274

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN： 1757-790X


  6 in total

1.  Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2.

Authors:  Jaishri O Blakeley; D Gareth Evans; John Adler; Derald Brackmann; Ruihong Chen; Rosalie E Ferner; C Oliver Hanemann; Gordon Harris; Susan M Huson; Abraham Jacob; Michel Kalamarides; Matthias A Karajannis; Bruce R Korf; Victor-Felix Mautner; Andrea I McClatchey; Harry Miao; Scott R Plotkin; William Slattery; Anat O Stemmer-Rachamimov; D Bradley Welling; Patrick Y Wen; Brigitte Widemann; Kim Hunter-Schaedle; Marco Giovannini
Journal:  Am J Med Genet A       Date:  2011-12-02       Impact factor: 2.802

Review 2.  Neurofibromatosis type 2.

Authors:  Ashok R Asthagiri; Dilys M Parry; John A Butman; H Jeffrey Kim; Ekaterini T Tsilou; Zhengping Zhuang; Russell R Lonser
Journal:  Lancet       Date:  2009-05-22       Impact factor: 79.321

3.  Human schwannomas express activated platelet-derived growth factor receptors and c-kit and are growth inhibited by Gleevec (Imatinib Mesylate).

Authors:  Joydeep Mukherjee; Deepak Kamnasaran; Anand Balasubramaniam; Ivan Radovanovic; Gelareh Zadeh; Tim-Rasmus Kiehl; Abhijit Guha
Journal:  Cancer Res       Date:  2009-06-09       Impact factor: 12.701

4.  Hearing improvement after bevacizumab in patients with neurofibromatosis type 2.

Authors:  Scott R Plotkin; Anat O Stemmer-Rachamimov; Fred G Barker; Chris Halpin; Timothy P Padera; Alex Tyrrell; A Gregory Sorensen; Rakesh K Jain; Emmanuelle di Tomaso
Journal:  N Engl J Med       Date:  2009-07-08       Impact factor: 91.245

5.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

Authors:  George D Demetri; Margaret von Mehren; Charles D Blanke; Annick D Van den Abbeele; Burton Eisenberg; Peter J Roberts; Michael C Heinrich; David A Tuveson; Samuel Singer; Milos Janicek; Jonathan A Fletcher; Stuart G Silverman; Sandra L Silberman; Renaud Capdeville; Beate Kiese; Bin Peng; Sasa Dimitrijevic; Brian J Druker; Christopher Corless; Christopher D M Fletcher; Heikki Joensuu
Journal:  N Engl J Med       Date:  2002-08-15       Impact factor: 91.245

6.  Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2.

Authors:  Sylwia Ammoun; Marei Caroline Schmid; Joceline Triner; Paul Manley; Clemens Oliver Hanemann
Journal:  Neuro Oncol       Date:  2011-07       Impact factor: 12.300
  6 in total
  1 in total

Review 1.  Childhood neurofibromatosis type 2 (NF2) and related disorders: from bench to bedside and biologically targeted therapies.

Authors:  M Ruggieri; A D Praticò; A Serra; L Maiolino; S Cocuzza; P Di Mauro; L Licciardello; P Milone; G Privitera; G Belfiore; M Di Pietro; F Di Raimondo; A Romano; A Chiarenza; M Muglia; A Polizzi; D G Evans
Journal:  Acta Otorhinolaryngol Ital       Date:  2016-10       Impact factor: 2.124
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.